Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
55M
-
Number of holders
-
84
-
Total 13F shares, excl. options
-
40.4M
-
Shares change
-
+587K
-
Total reported value, excl. options
-
$535M
-
Value change
-
+$3.68M
-
Number of buys
-
46
-
Number of sells
-
-31
-
Price
-
$13.21
Significant Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q2 2022
99 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2022.
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) has 84 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.4M shares
of 55M outstanding shares and own 73.5% of the company stock.
Largest 10 shareholders include Skorpios Trust (14.4M shares), RTW INVESTMENTS, LP (3.65M shares), FMR LLC (2.96M shares), VANGUARD GROUP INC (2M shares), Redmile Group, LLC (1.99M shares), BlackRock Inc. (1.7M shares), COWEN AND COMPANY, LLC (1.51M shares), WELLINGTON MANAGEMENT GROUP LLP (1.26M shares), Cormorant Asset Management, LP (1.09M shares), and BANK OF MONTREAL /CAN/ (1.01M shares).
This table shows the top 84 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.